Tier 2 — strong

alpha-Oligoglucosylation of a sugar moiety enhances the bioavailability of quercetin glucosides in humans

Kaeko Murota, Namiko Matsuda, Yasuaki Kashino, Yutaka Fujikura, Toshiyuki Nakamura, Yoji Kato, Ryosuke Shimizu, Syuji Okuyama, Hisashi Tanaka, Takatoshi Koda, Keiko Sekido, Junji Terao
Archives of biochemistry and biophysics 2010 501(1):91

Bibliography

PubMed
PMID 20638359
DOI
10.1016/j.abb.2010.06.036
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignComparative human glycoside absorption study
ModelHuman intervention research
SampleHuman volunteers; sample size not stated in the indexed abstract
InterventionEnzymatically modified isoquercitrin compared with isoquercitrin and rutin
DurationAcute oral absorption comparisons
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2010, this source examined forms, absorption and food sources. Design: Comparative human glycoside absorption study. Sample/model: Human volunteers; sample size not stated in the indexed abstract. The exposure or intervention was Enzymatically modified isoquercitrin compared with isoquercitrin and rutin. Follow-up or treatment period: Acute oral absorption comparisons.

The modified glycoside produced greater exposure to quercetin metabolites than the comparator glycosides.

The finding is formulation-specific and pharmacokinetic. Exact doses and sample size need full-method confirmation; greater exposure is not proven clinical superiority.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The modified glycoside produced greater exposure to quercetin metabolites than the comparator glycosides.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Enzymatically modified isoquercitrin compared with isoquercitrin and rutin; Acute oral absorption comparisons.

What this study can and cannot tell us

  • The finding is formulation-specific and pharmacokinetic. Exact doses and sample size need full-method confirmation; greater exposure is not proven clinical superiority.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology